- Home
- CRNX
as 02-21-2025 4:00pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Upcoming Earnings Alert:
Get ready for potential market movements as Crinetics Pharmaceuticals Inc. CRNX prepares to release earnings report on 27 Feb 2025.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 5.2B | IPO Year: | 2018 |
| Target Price: | $72.64 | AVG Volume (30 days): | 710.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $34.07 - $62.53 | Next Earning Date: | 02-27-2025 |
| Revenue: | $1,038,999 | Revenue Growth: | -78.00% |
| Revenue Growth (this year): | -58.14% | Revenue Growth (next year): | 206.01% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Feb 3 '25 | Sell | $39.07 | 5,000 | $195,350.00 | 31,748 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Jan 3 '25 | Sell | $52.09 | 15,000 | $781,350.00 | 31,748 | |
| Struthers Richard Scott | CRNX | President & CEO | Dec 2 '24 | Sell | $57.57 | 10,000 | $575,700.00 | 100,000 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
MT Newswires
11 days ago
TD Cowen Initiates Crinetics Pharmaceuticals at Buy
GlobeNewswire
12 days ago
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
16 days ago
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Insider Monkey
17 days ago
Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers
MT Newswires
18 days ago
Wolfe Research Initiates Coverage on Crinetics Pharmaceuticals With Peer Perform Rating
Insider Monkey
24 days ago
What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)?
MT Newswires
a month ago
Jefferies Upgrades Crinetics Pharmaceuticals to Buy From Hold, $55 Price Target
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.